APA (7th ed.) Citation

L, S., F, R., E, B., G, P., M, G., S, C., . . . M, B. (2026). Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. American journal of cardiovascular drugs : drugs, devices, and other interventions, 26(1), 21. https://doi.org/10.1007/s40256-025-00757-6

Chicago Style (17th ed.) Citation

L, Spadafora, et al. "Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 26, no. 1 (2026): 21. https://doi.org/10.1007/s40256-025-00757-6.

MLA (9th ed.) Citation

L, Spadafora, et al. "Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 26, no. 1, 2026, p. 21, https://doi.org/10.1007/s40256-025-00757-6.